Marc Iskowitz’ latest post sets the stage for the MM&M/Deloitte Healthcare Marketers Trend Report, which will be published on Monday morning. The op-ed dives into the issue of a significant increase in funding for healthcare communications at a time when there is profound skepticism of the pharma industry. (MM&M)

GW Pharmaceuticals’ cannabis-based treatment for rare forms of epilepsy beat Wall Street’s expectations. Net sales totaled $4.7 million for November and December in comparison to the forecasted $2.5 million. Epidiolex is the first cannabis-derived treatment approved in the U.S. CEO Justin Gover spoke with MM&M about the company’s marketing plan for both patients and providers. (Biopharma Dive)

Amazon’s Nader Kabbani has been appointed to run its pharmacy business. His new role is VP of consumables, special projects. The entire PillPack team, acquired in June 2018 for $800 million, will report to Kabbani. Previously, Kabbani was VP of Amazon Flex. (CNBC)

Rep. Mark Meadows (R-NC) questioned Michael Cohen about his relationship with Novartis on Wednesday during congressional testimony. Cohen said that Novartis wanted him to lobby on behalf of the company, but he declined. Novartis responded by saying it considers the matter closed. (Endpoints)

MM&M’s latest podcast features Razorfish Health’s Tayla Mahmud. She chats with Marc Iskowitz about the lack of diversity in drug development and her roundtable at MM&M‘s upcoming Plus One event. (MM&M)